Navigation Links
Antibiotic Combo Fights Resistant TB
Date:2/26/2009

2 FDA-approved drugs inhibit both normal and virulent strains, study finds

THURSDAY, Feb. 26 (HealthDay News) -- Combination treatment with two FDA-approved drugs shows promise in treating extensively drug-resistant tuberculosis (XDR-TB), a U.S. study shows.

In laboratory tests, researchers at the Albert Einstein College of Medicine and the National Institute of Allergy and Infectious Diseases found that a combination of the drugs clavulanate and meropenem inhibited the growth of 13 XDR-TB strains. The combination treatment was also effective against normal TB. Both drugs are approved in the United States for treating other bacterial infections in adults and children.

The study was published in the Feb. 27 issue of Science.

Current therapy for normal TB requires four antibiotics that must be taken for at least six months. XDR-TB is resistant to at least four of the drugs used to treat TB. The cure rate for patients with XDR-TB is 12 percent to 60 percent.

"If proven in human subjects, the ability to simplify treatment to just two drugs that work against drug-susceptible [TB], multi-drug-resistant [TB] and XDR-TB could help patients better adhere to therapy," study senior author John S. Blanchard, a professor of biochemistry at Einstein, said in a college news release.

"This discovery could be one of the most promising developments in TB research since the discovery of isoniazid -- it is very exciting," William Jacobs, a professor of microbiology and immunology at Einstein and associate director of the Einstein-Montefiore Center for AIDS Research, said in the news release. Isoniazid, the first effective anti-tuberculosis medication, was discovered in the 1950s.

Plans are under way for clinical studies in Korea and in South Africa to determine whether the combination treatment is effective in patients with XDR-TB.

This highly dangerous form of TB is rare in the United States, with only 83 documented cases in the country between 1993 and 2007. However, XDR-TB is emerging as a serious problem in some developing nations.

More information

The U.S. Centers for Disease Control and Prevention has more about XDR-TB.



-- Robert Preidt



SOURCE: Albert Einstein College of Medicine, news release, Feb. 26, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New antibiotic drug combo to speed up treatment of tuberculosis
2. Newer Antibiotic Speeds TB Healing
3. Antibiotics Not Always Best Bet for Battling Childhood Ear Infections
4. Antibiotic Shows Promise as Stroke Treatment
5. Ear infection superbug discovered to be resistant to all pediatric antibiotics
6. Antibiotics May Not Help Mens Chronic Pelvic Pain: Harvard Doctors Discuss Alternatives
7. Study Shows Antibiotic Harms ALS Patients
8. Dragon Sells EPO Business; Focus on Antibiotic Core Business
9. Drug Combo With Antibiotic May Slow MS Progression
10. Antibiotic treatment targets difficult asthma
11. New Report Underscores Need for Congressional Action to Limit Antibiotic Use in Animal Agriculture
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Antibiotic Combo Fights Resistant TB
(Date:4/28/2017)... ... 28, 2017 , ... Children and adolescents who enter the ... children in the general population. That’s because foster care is designed to protect ... While no fault of their own, youth who have experienced trauma often have ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... could substantially improve drug safety and minimize the cost of development. In this ... channel inhibition using cell lines and for cardiac toxicity using induced pluripotent stem ...
(Date:4/28/2017)... Abilene, Texas (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... says, reveals which name the Creator responds to and which He does not. Yisrayl ... to believe which one is the true name, but he says with a little Scripture, ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to ... ERP expert that specializes in long-term care, Brooke Grove now has the capability ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a ... he has leant his presence to an educational purpose as the host of the ... one being cancer. In a recent episode, the series focuses on thyroid cancer. , ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
Breaking Medicine Technology: